33013289|t|Abnormal Serum Bilirubin/Albumin Concentrations in Dementia Patients With Abeta Deposition and the Benefit of Intravenous Albumin Infusion for Alzheimer's Disease Treatment.
33013289|a|BACKGROUND: Our previous study in animal models revealed that bilirubin could induce Abeta formation and deposition. Bilirubin may be important in neurodegenerative dementia with Abeta deposition. Hence, lowering the concentration of the free bilirubin capable of crossing the blood brain-barrier may benefit the treatment of Alzheimer's disease (AD). OBJECTIVES: The objectives of this study were to examine the change in the serum bilirubin and albumin concentrations of dementia patients with Abeta deposition, and to determine the effects of intravenous administration of albumin in the treatment of AD. METHODS: Bilirubin and albumin concentrations in dementia patients with Abeta deposition were examined. Cell viability and apoptosis were determined in dopaminergic neuron-like cells MN9D treated with bilirubin in the presence of diverse concentrations of serum. Human albumin at a dose of 10 g every 2 weeks for 24 weeks was administered intravenously to AD patients to examine the effect of albumin on AD symptoms. RESULTS: Significantly higher indirect bilirubin (IBIL) concentrations, lower albumin concentrations, and higher ratio of IBIL to albumin (IBIL/ALB) were observed in dementia patients with Abeta deposition, including AD, dementia with Lewy bodies, and general paresis of insane. In vitro assays showed that bilirubin-induced injury in cultured dopaminergic neuron-like cells negatively depends on the concentration of serum in the culture medium. General linear model with repeated measures analysis indicated a main effect of group on the change in albumin concentrations and Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL) scores, and the main effect of time and group, and group-by-time interaction on the change of Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) scores. Analysis of the combined data of the entire 28 weeks of assessment period using the area under curve convincingly showed significantly improvements in the change of albumin concentrations, ADCS-ADL scores, and CDR-SB scores. CONCLUSION: IBIL and the IBIL/ALB ratio are significantly higher in dementia patients with Abeta deposition, and intravenous administration of albumin is beneficial to AD treatment. TRIAL REGISTRATION: The intervention study was registered at http://www.chictr.org.cn (ChiCTR-IOR-17011539). Date of registration: June 1, 2017.
33013289	15	24	Bilirubin	Chemical	MESH:D001663
33013289	25	32	Albumin	Gene	213
33013289	51	59	Dementia	Disease	MESH:D003704
33013289	60	68	Patients	Species	9606
33013289	74	79	Abeta	Gene	351
33013289	122	129	Albumin	Gene	213
33013289	143	162	Alzheimer's Disease	Disease	MESH:D000544
33013289	236	245	bilirubin	Chemical	MESH:D001663
33013289	259	264	Abeta	Gene	351
33013289	291	300	Bilirubin	Chemical	MESH:D001663
33013289	321	347	neurodegenerative dementia	Disease	MESH:D019636
33013289	353	358	Abeta	Gene	351
33013289	417	426	bilirubin	Chemical	MESH:D001663
33013289	500	519	Alzheimer's disease	Disease	MESH:D000544
33013289	521	523	AD	Disease	MESH:D000544
33013289	607	616	bilirubin	Chemical	MESH:D001663
33013289	621	628	albumin	Gene	213
33013289	647	655	dementia	Disease	MESH:D003704
33013289	656	664	patients	Species	9606
33013289	670	675	Abeta	Gene	351
33013289	750	757	albumin	Gene	213
33013289	778	780	AD	Disease	MESH:D000544
33013289	791	800	Bilirubin	Chemical	MESH:D001663
33013289	805	812	albumin	Gene	213
33013289	831	839	dementia	Disease	MESH:D003704
33013289	840	848	patients	Species	9606
33013289	854	859	Abeta	Gene	351
33013289	947	953	neuron	Disease	MESH:D009410
33013289	965	969	MN9D	CellLine	CVCL:M067
33013289	983	992	bilirubin	Chemical	MESH:D001663
33013289	1045	1058	Human albumin	Species	
33013289	1138	1140	AD	Disease	MESH:D000544
33013289	1141	1149	patients	Species	9606
33013289	1175	1182	albumin	Gene	213
33013289	1186	1188	AD	Disease	MESH:D000544
33013289	1238	1247	bilirubin	Chemical	MESH:D001663
33013289	1249	1253	IBIL	Chemical	-
33013289	1277	1284	albumin	Gene	213
33013289	1321	1325	IBIL	Chemical	-
33013289	1329	1336	albumin	Gene	213
33013289	1338	1342	IBIL	Chemical	-
33013289	1365	1373	dementia	Disease	MESH:D003704
33013289	1374	1382	patients	Species	9606
33013289	1388	1393	Abeta	Gene	351
33013289	1416	1418	AD	Disease	MESH:D000544
33013289	1420	1445	dementia with Lewy bodies	Disease	MESH:D020961
33013289	1459	1476	paresis of insane	Disease	MESH:D009494
33013289	1506	1515	bilirubin	Chemical	MESH:D001663
33013289	1556	1562	neuron	Disease	MESH:D009410
33013289	1749	1756	albumin	Gene	213
33013289	1776	1795	Alzheimer's Disease	Disease	MESH:D000544
33013289	1971	1979	Dementia	Disease	MESH:D003704
33013289	2188	2195	albumin	Gene	213
33013289	2260	2264	IBIL	Chemical	-
33013289	2273	2277	IBIL	Chemical	-
33013289	2316	2324	dementia	Disease	MESH:D003704
33013289	2325	2333	patients	Species	9606
33013289	2339	2344	Abeta	Gene	351
33013289	2391	2398	albumin	Gene	213
33013289	2416	2418	AD	Disease	MESH:D000544
33013289	Association	MESH:D009494	351
33013289	Negative_Correlation	MESH:D000544	213
33013289	Negative_Correlation	213	351
33013289	Association	MESH:D003704	213
33013289	Association	MESH:D019636	351
33013289	Association	MESH:D001663	MESH:D019636
33013289	Negative_Correlation	MESH:D001663	MESH:D009410
33013289	Association	MESH:D020961	351
33013289	Association	MESH:D001663	MESH:D003704
33013289	Association	MESH:D009494	213
33013289	Association	MESH:D001663	MESH:D000544
33013289	Association	MESH:D003704	351
33013289	Association	MESH:D020961	213
33013289	Positive_Correlation	MESH:D001663	MESH:D020961
33013289	Positive_Correlation	MESH:D001663	351
33013289	Association	MESH:D000544	351
33013289	Positive_Correlation	MESH:D001663	MESH:D009494

